JOHNSON LAU
Dunkirk’s new Athenex facility is nearing completion as company officials continue pushing for federal approval for its new breast cancer treatment.
Athenex has yet to meet with the federal government to address a FDA complete response letter that slowed approval of the company’s new breast cancer treatment. The FDA’s decision in February dealt a hit to Athenex’ stock prices as well as to the company’s bottom line.
Still, company officials are moving full steam ahead with Athenex’ Dunkirk facility, according to Jeff Yordon, Athenex chief operating officer, who spoke during a recent conference call with investor analysts.
jwhittaker@post-journal.com
Johnson Lau, Athenex chief executive officer, said a meeting with the FDA could happen later this month.
Dunkirk’s new Athenex facility is nearing completion as company officials continue pushing for federal approval for its new breast cancer treatment.
Athenex has yet to meet with the federal government to address a FDA complete response letter that slowed approval of the company’s new breast cancer treatment. The FDA’s decision in February dealt a hit to Athenex’ stock prices as well as to the company’s bottom line.
Still, company officials are moving full steam ahead with Athenex’ Dunkirk facility, according to Jeff Yordon, Athenex chief operating officer, who spoke during a recent conference call with investor analysts.